In vivo modelling of cutaneous T-cell lymphoma: The role of SOCS1

被引:3
|
作者
Luo, Yixin [1 ]
Vermeer, Maarten H. [1 ]
de Gruijl, Frank R. [1 ]
Zoutman, Willem H. [1 ]
Sluijter, Marjolein [2 ]
van Hall, Thorbald [2 ]
Tensen, Cornelis P. [1 ]
机构
[1] Leiden Univ Med Ctr, Dept Dermatol, Leiden, Netherlands
[2] Leiden Univ Med Ctr, Oncode Inst, Dept Med Oncol, Leiden, Netherlands
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
cutaneous T cell lymphoma; mycosis fungoides; transgenic mouse; in vivo modeling; inflammation; CHRONIC SKIN INFLAMMATION; MOUSE EPIDERMIS REVEAL; CYTOKINE SIGNALING-1; IFN-GAMMA; STAT3; EXPRESSION; CANCER; ACTIVATION; SUPPRESSOR; SUPPRESSOR-OF-CYTOKINE-SIGNALING-1;
D O I
10.3389/fonc.2022.1031052
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
IntroductionMycosis fungoides (MF), the most common type of Cutaneous T cell Lymphoma (CTCL), is characterized by an inflamed skin intermixed with proliferating malignant mature skin-homing CD4+ T cells. Detailed genomic analyses of MF skin biopsies revealed several candidate genes possibly involved in genesis of these tumors and/or potential targets for therapy. These studies showed, in addition to common loss of cell cycle regulator CDKN2A, activation of several oncogenic pathways, most prominently and consistently involving JAK/STAT signaling. SOCS1, an endogenous inhibitor of the JAK/STAT signaling pathway, was identified as a recurrently deleted gene in MF, already occurring in the earliest stages of the disease. MethodsTo explore the mechanisms of MF, we create in vivo mouse models of autochthonous CTCLs and these genetically engineered mouse models (GEMMS) can also serve as valid experimental models for targeted therapy. We describe the impact of allelic deletion of Socs1 in CD4 T cells of the skin. To achieve this, we crossed inducible Cre-transgenic mice in the CD4 lineage with transgenic mice carrying floxed genes of Socs1. We first determined optimal conditions for Socs1 ablation with limited effects on circulating CD4 T-cells in blood. Next, we started time-course experiments mimicking sustained inflammation, typical in CTCL. FACS analysis of the blood was done every week. Skin biopsies were analyzed by immunocytochemical staining at the end of the experiment. ResultsWe found that the Socs1 knockout transgenic group had thicker epidermis of treated skin compared with the control group and had more CD3 and CD4 in the skin of the transgenic group compared to the control group. We also noted more activation of Stat3 by staining for P-Stat3 in Socs1 knockout compared to wt CD4+T cells in the skin. The results also indicated that single copy loss of Socs1 in combination with sustained inflammation is insufficient to start a phenotype resembling early stage mycosis fungoides within eight weeks in these mice. ConclusionIn sum, we developed and optimized an autochthonous murine model permitting selective knockout of Socs1 in skin infiltrating CD4 T-cells. This paves the way for more elaborate experiments to gain insight in the oncogenesis of CTCL.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] MULTIINSTITUTIONAL STUDY OF CUTANEOUS T-CELL LYMPHOMA AND ADULT T-CELL LEUKEMIA-LYMPHOMA
    NAGATANI, T
    MIYAGAWA, K
    BABA, N
    FUKAYA, T
    HAMADA, T
    HIRONE, T
    HISADOME, H
    HONBO, S
    HORI, Y
    IMAMURA, S
    INOUE, S
    ITO, M
    IWATSUKI, K
    JOHNO, M
    KOBAYASHI, H
    KUROKI, Y
    MIYAMOTO, H
    NAKAJIMA, H
    NAKAYAMA, J
    OKAWARA, A
    OGATA, K
    ONO, T
    SATO, Y
    TAKATA, M
    TAKEZAKI, S
    TASHIRO, M
    YAMAGUCHI, S
    YAMADA, M
    EUROPEAN JOURNAL OF DERMATOLOGY, 1994, 4 (04) : 299 - 303
  • [32] SOCS1 Prevents Graft Arteriosclerosis by Preserving Endothelial Cell Function
    Qin, Lingfeng
    Huang, Qunhua
    Zhang, Haifeng
    Liu, Renjing
    Tellides, George
    Min, Wang
    Yu, Luyang
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (01) : 21 - 29
  • [33] Infectious agents in cutaneous T-cell lymphoma
    Mirvish, Ezra D.
    Pomerantz, Rebecca G.
    Geskin, Larisa J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : 423 - 431
  • [34] Erythrodermic syringotropic cutaneous T-cell lymphoma
    Ah-Weng, A
    Howatson, SR
    Goodlad, JR
    Patel, MC
    Gupta, G
    BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (02) : 349 - 352
  • [35] Update on treatment of cutaneous T-cell lymphoma
    Gardner, Jennifer M.
    Evans, Katherine G.
    Musiek, Amy
    Rook, Alain H.
    Kim, Ellen J.
    CURRENT OPINION IN ONCOLOGY, 2009, 21 (02) : 131 - 137
  • [36] Forodesine in the treatment of cutaneous T-cell lymphoma
    Lewis, Daniel J.
    Duvic, Madeleine
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (06) : 771 - 775
  • [37] Update on Epidemiology of Cutaneous T-Cell Lymphoma
    Samimi S.
    Rook A.H.
    Kim E.J.
    Current Dermatology Reports, 2013, 2 (1) : 35 - 41
  • [38] Cutaneous T-Cell Lymphoma: Roles for Chemokines and Chemokine Receptors
    Wu, Xue-Song
    Lonsdorf, Anke S.
    Hwang, Sam T.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 (05) : 1115 - 1119
  • [39] Cutaneous T-cell lymphoma and atopy: is there an association?
    Mehrany, K
    El-Azhary, RA
    Bouwhuis, SA
    Pittelkow, MR
    BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 (05) : 1013 - 1017
  • [40] Molecular advances in cutaneous T-cell lymphoma
    Torres, Armando N. Bastidas
    Najidh, Safa
    Tensen, Cornelis P.
    Vermeer, Maarten H.
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2018, 37 (01) : 81 - 85